Uveitis Drugs Market to grow with a CAGR of 7.20%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Uveitis Drugs Market.
According
to TechSci Research report, “Global Uveitis Drugs Market Industry Size,
Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Uveitis Drugs Market
has valued at USD 705.30 million in 2022 and is anticipated to witness an
impressive growth in the forecast period with a CAGR of 7.20% through
2028. This can be due to collaborations
and partnerships among leading companies with a diverse approach to merge the
expertise of individual companies and to strengthen their position in the
market.
The
growing aging population is a significant driver of the demand for uveitis
drugs in the Global Uveitis Drugs Market. Uveitis is an eye condition that can
affect individuals of all ages, but its prevalence tends to increase with age.
Uveitis is more commonly diagnosed in older individuals. As people age, their
immune system may undergo changes that can make them more susceptible to
autoimmune and inflammatory conditions, including uveitis. The aging process is
associated with an increased risk of age-related eye conditions, such as
cataracts, age-related macular degeneration (AMD), and diabetic retinopathy.
Some of these conditions can lead to secondary uveitis or complications that
require uveitis drugs as part of the treatment. Aging is often accompanied by
an increased prevalence of systemic diseases, including autoimmune conditions
and infections, which can trigger or exacerbate uveitis. Managing these
systemic diseases may involve the use of uveitis drugs. Elderly individuals may
have a history of corticosteroid use for various medical conditions. Long-term
corticosteroid use can lead to eye conditions such as corticosteroid-induced
glaucoma and cataracts, which may require uveitis drugs for treatment.
The
frequency of uveitis with infectious aetiologies is increasing along with the
incidence of infectious illnesses. It is mainly prevalent in poorer nations.
Around 50% of uveitis cases in India, according to the Indian Journal of
Inflammation Research, are brought on by infections. Due to viral aetiologies,
developing nations are also quite prone to ocular irritation.
In
October 2018, The U.S. Food and Drug Administration (FDA) has approved YUTIQ
(fluocinolone acetonide intravitreal implant) for the treatment of chronic
non-infectious uveitis affecting the posterior segment of the eye, according to
EyePoint Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated
to developing and commercializing innovative ophthalmic products. YUTIQ is a
non-bioerodible intravitreal micro-insert in a drug delivery system containing
0.18 mg fluocinolone acetonide that is intended to release steadily over a
36-month period. It uses the company's Durasert drug delivery technology. YUTIQ
is provided in a preloaded, single-dose sterile applicator that may be used to
deliver the medication at a doctor's office. The prevalence of recurrent
uveitis flares was considerably lower with YUTIQ in clinical studies compared
to placebo, and the most frequent side effects were cataract formation and a
rise in intraocular pressure (IOP).
Browse over XX market data Figures and spread through 110 Pages and an
in-depth TOC on "Uveitis Drugs Market”
Limited
treatment options can be a challenge in the Global Uveitis Drugs Market.
Uveitis is a complex and heterogeneous condition with various underlying causes
and manifestations. Uveitis encompasses several distinct forms, including
anterior, intermediate, posterior, and panuveitis, each with its unique characteristics
and underlying causes. Treatment approaches need to be tailored to the specific
type of uveitis, and this diversity can make it challenging to develop a
one-size-fits-all treatment. Uveitis can be associated with a wide range of
underlying causes, including infections, autoimmune diseases, and idiopathic
(unknown) factors. Identifying and addressing the underlying cause is crucial
for effective treatment. In some cases, determining the cause can be
challenging.
Global Uveitis Drugs Market segmentation is based on Treatment Type, Disease Type, Cause, Distribution Channel, Region and Company
Based
on Disease Type, Global Uveitis Drugs Market is segmented into Anterior
Uveitis, Intermediate Uveitis, Panuveitis, Posterior Uveitis. Posterior uveitis
is a type of uveitis, which is an inflammatory condition that affects the uvea,
the middle layer of the eye. Posterior uveitis specifically involves
inflammation in the posterior segment of the eye, which includes the choroid,
retina, and optic nerve. This form of uveitis can be serious and may lead to
vision impairment or loss if not promptly diagnosed and treated. In posterior
uveitis, inflammation occurs in the back of the eye, primarily affecting the
choroid, which is a layer of blood vessels that supply nutrients to the retina.
The retina, the light-sensitive tissue at the back of the eye responsible for
vision, can also become inflamed. In severe cases, the optic nerve, which
transmits visual information to the brain, may be involved. Regular follow-up visits with an
ophthalmologist are essential to monitor the response to treatment and assess
for any potential complications or disease recurrence.
Based on Region, North America dominated the Global Uveitis Drugs Market.
The United States has a well-established regulatory framework for drug approval
and safety monitoring. The rigorous regulatory process ensures that effective
and safe uveitis drugs are available to patients. Many residents in North
America have healthcare insurance coverage, which can help offset the costs of
uveitis treatment, including prescription medications. This can improve patient
access to necessary drugs. There is a strong emphasis on patient education and
awareness regarding eye health and conditions like uveitis. This can lead to
earlier diagnosis and treatment. North America often serves as a hub for
clinical trials of new uveitis drugs. The region's well-developed clinical
trial infrastructure and patient participation contribute to the development and
approval of new treatments. North America has a robust pharmaceutical market,
attracting investments from global pharmaceutical companies. This encourages
the availability of uveitis drugs in the region.
Asia-pacific region to fastest growth in
the Global Uveitis Drugs Market. The Asia-Pacific region has seen a rise in the
incidence of uveitis, which can be attributed to factors such as changes in
lifestyle, environmental factors, and improved diagnostic capabilities. As more
cases are diagnosed, the demand for uveitis drugs is growing. Like many parts
of the world, the Asia-Pacific region is experiencing demographic shifts, with
a growing aging population. Uveitis is more common in older individuals, so the
increase in the elderly population contributes to higher uveitis prevalence.
Improvements in healthcare infrastructure and increased awareness about eye
health have led to earlier detection and treatment of eye conditions, including
uveitis. The growing middle-class population in the Asia-Pacific region has
increased the affordability of healthcare services, including specialized eye
care. This has encouraged more people to seek treatment for uveitis.
Some
of the major companies operating in the Global
Uveitis Drugs Market include:
- Allergan
Inc.
- Bausch
& Lomb Incorporated
- Santen
Pharmaceutical Co. Ltd
- AbbVie
Inc.
- Novartis
AG
- Eyegate
Pharmaceuticals Inc.
- Regeneron
Pharmaceuticals
- Eyepoint
pharmaceuticals Inc.
- Alimera
Sciences Inc.
Download Free Sample Report
Customers can also request
10% free customization on this report
“Certain areas, particularly in North
America, are projected to exert significant demand for Uveitis Drugs. The
growth in the competitive landscape and the presence of well-established
companies in the market, committed to enhance the overall wellbeing of people each
year, are expected to contribute to a remarkable growth of the Global Uveitis
Drugs Market in the forecast period," said Mr. Karan Chechi, Research
Director with TechSci Research, a research-based Global management consulting
firm.
Uveitis Drugs Market – Global Industry Size,
Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Treatment Type
(Analgesics, Antibiotics, Antifungal, Antivirals, Corticosteroids, Cycloplegic
Agents, Immunosuppressant, Monoclonal Antibodies) by Disease Type (Anterior
Uveitis, Intermediate Uveitis, Panuveitis, Posterior Uveitis), by Cause
(Infectious, Noninfectious), by Distribution Channel (Hospital Pharmacies,
Online Pharmacies, Retail Pharmacies), by region, and Competition evaluated
the future growth potential of Global Uveitis Drugs Market and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide innovative market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Uveitis Drugs Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York 10017
Tel:
+1-646-360-1656
Email: [email protected]
Website: www.techsciresearch.com